Preprint · 2026 · Open access
Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition
bioRxiv (Cold Spring Harbor Laboratory) · Published 18 September 2026 · DOI 10.64898/2026.09.16.752096
In brief
“Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition” is a 2026 preprint by Michael P. East and 27 co-authors, published in bioRxiv (Cold Spring Harbor Laboratory). OpenAlex counts 0 citations as of 21 November 2026. It is open access: the full text is free to read at bioRxiv (Cold Spring Harbor Laboratory).
- Citations
- 0
- References
- 34
- Authors
- 28
Abstract
Triple-Negative Breast Cancer (TNBC) is a clinical subtype where aberrant expression of receptor tyrosine kinases (RTKs) leads to the activation of the RAS-RAF-MEK-ERK pathway contributing to tumor progression. Therapies targeting components of the RAF-MEK-ERK pathway in TNBC have been disappointing due to rapid onset of adaptive reprogramming of the RTK landscape leading to pathway reactivation. To overcome the dynamic heterogeneity of RTK expression and their convergence in activating RAS, treatment with the pan-RAS(on) inhibitor daraxonrasib (RMC-6236), which inhibits RAS-GTP regulation of RAF kinases, inhibited proliferation independent of TNBC kinotype or oncogenic RAS mutation in three of four TNBC cell lines in vitro and two patient-derived TNBC xenografts in mice. Daraxonrasib in combination with the MEK inhibitor trametinib prevented reactivation of the RAF-MEK-ERK pathway observed with each inhibitor alone and further enhanced inhibition of tumor growth in TNBC cell lines and xenografts. Inhibiting pan-RAS(on) RAS-GTP, with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
East, M. P., Olivares-Quintero, J. F., Okumu, D. O., Mott, K. R., Sprung, R. W., Whitman, A. A., Joisa, C. U., Chen, X., Zhang, Q., Erdmann-Gilmore, P., Mi, Y., Malone, J. P., Bhatia, S., McCabe, I. C., Xu, Y., Sutcliffe, M. D., Spears, P. A., Zawistowski, J. S., Perou, C. M., . . . Johnson, G. L. (2026). Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.64898/2026.09.16.752096
MLA 9
East, Michael P., et al. “Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.” bioRxiv (Cold Spring Harbor Laboratory), 2026. https://doi.org/10.64898/2026.09.16.752096.
Chicago
East, Michael P., José F. Olivares-Quintero, Denis O. Okumu, Kevin Raynard Mott, Robert W. Sprung, Austin A. Whitman, Chinmaya U. Joisa, et al. 2026. “Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.” bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.64898/2026.09.16.752096.
Harvard
East, M. P. et al. (2026) ‘Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition’, bioRxiv (Cold Spring Harbor Laboratory). doi:10.64898/2026.09.16.752096.
IEEE
M. P. East et al., “Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition,” bioRxiv (Cold Spring Harbor Laboratory), 2026, doi: 10.64898/2026.09.16.752096.
BibTeX
@misc{east2026vulnerability,
title = {{Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition}},
author = {East, Michael P. and Olivares-Quintero, José F. and Okumu, Denis O. and Mott, Kevin Raynard and Sprung, Robert W. and Whitman, Austin A. and Joisa, Chinmaya U. and Chen, Xin and Zhang, Qiang and Erdmann-Gilmore, Petra and Mi, Yiling and Malone, James P. and Bhatia, Sonam and McCabe, Ian C. and Xu, Yi and Sutcliffe, Matthew D. and Spears, Patricia A. and Zawistowski, Jon S. and Perou, Charles M. and Earp, Henry Shelton and Carey, LA and Yeh, Jen Jen and Spector, David L. and Stover, Daniel G. and Gomez, Shawn M. and Spanheimer, Philip M. and Townsend, R. Reid and Johnson, Gary L.},
howpublished = {bioRxiv (Cold Spring Harbor Laboratory)},
year = {2026},
doi = {10.64898/2026.09.16.752096},
url = {https://doi.org/10.64898/2026.09.16.752096}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- triple-negative breast cancer
- daraxonrasib
- RMC-6236
- Ras-GTP
- Raf/MEK/ERK pathway
- receptor tyrosine kinase
- trametinib
- MEK inhibitors
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
East, M. P., Olivares-Quintero, J. F., Okumu, D. O., Mott, K. R., Sprung, R. W., Whitman, A. A., Joisa, C. U., Chen, X., Zhang, Q., Erdmann-Gilmore, P., Mi, Y., Malone, J. P., Bhatia, S., McCabe, I. C., Xu, Y., Sutcliffe, M. D., Spears, P. A., Zawistowski, J. S., Perou, C. M., . . . Johnson, G. L. (2026). Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.64898/2026.09.16.752096
How many times has this paper been cited?
0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at bioRxiv (Cold Spring Harbor Laboratory): sign in and open the PDF from this page.
Who wrote this paper?
Michael P. East, José F. Olivares-Quintero, Denis O. Okumu, Kevin Raynard Mott, Robert W. Sprung, Austin A. Whitman, Chinmaya U. Joisa, Xin Chen, Qiang Zhang, Petra Erdmann-Gilmore, Yiling Mi, James P. Malone and 16 more.
What is the DOI of this paper?
10.64898/2026.09.16.752096, permanently at https://doi.org/10.64898/2026.09.16.752096. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.